(Reuters) -The director of the U.S. Food and Drug Administration's Center for Drug Evaluation and Research, George Tidmarsh, resigned on Sunday amid serious concerns about his personal conduct, a Department of Health and Human Services spokesperson told Reuters on Monday.

The Trump administration on Thursday announced its newest pharmaceutical agreement under its Most Favored Nation (MFN) policy, striking deals with Novo Nordisk and Eli Lilly to sell their GLP-1

The dramatic shift in oversight comes at a time when the U.S. has never been more reliant on foreign food, which accounts for the vast majority of the nation’s seafood and more than half its fresh fruit.

(Reuters) -The U.S. Food and Drug Administration said on Thursday it has awarded six more companies, including Eli Lilly and Novo Nordisk, special vouchers that will speed up the review of their medicines, bringing the total number of recipients to 15. The vouchers went to treatments for cancer, obesity, tuberculosis and sickle cell disease.

The top drug regulator at the Food and Drug Administration (FDA) resigned Sunday, according to officials, after being accused of using his position of authority to publicly denigrate a treatment tied to a former business associate.

The FDA has sent warning letters to 18 websites selling counterfeit or unapproved versions of Botox and similar injectable drugs commonly used to smooth wrinkles.

More than 140,000 bottles of a popular drug commonly prescribed to reduce cholesterol have been recalled for a defect that could make the medication less effective.

The head of the U.S. Food and Drug Administration’s drug division, Dr. George F. Tidmarsh, resigned on November 2, 2025, one day before he was named in a federal defamation lawsuit filed in Maryland by Aurinia Pharmaceuticals Inc.

New professional guidance to the nation's pediatricians advises against using a drug in children with autism that many families are clamoring for after it was hyped by federal officials.